EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines
The first approved COVID‐19 vaccines include Pfizer/BioNTech BNT162B2, Moderna
mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval …
mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval …
Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
L Klimek, KC Bergmann, R Brehler, W Pfützner… - Allergo journal …, 2021 - Springer
Background For the preventive treatment of the 2019 coronavirus disease (COVID-19) an
unprecedented global research effort studied the safety and efficacy of new vaccine …
unprecedented global research effort studied the safety and efficacy of new vaccine …
Allergy to COVID-19 vaccines: a current update
B Cabanillas, N Novak - Allergology International, 2021 - jstage.jst.go.jp
abstract Adverse allergic reactions due to the administration of the vaccines developed for
the protection of coronavirus disease 2019 (COVID-19) have been reported since the …
the protection of coronavirus disease 2019 (COVID-19) have been reported since the …
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines–an EAACI‐ARIA position paper
Further to the approval of the Coronavirus disease 2019 (COVID‐19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …
several severe anaphylaxis cases occured within the first few days of public vaccination. An …
[HTML][HTML] Severe allergic reactions to the COVID-19 vaccine–statement and practical consequences
J Kleine-Tebbe, L Klimek, E Hamelmann… - Allergologie …, 2021 - ncbi.nlm.nih.gov
On December 10, 2020, the BBC reported two allergic adverse events following the first
injection of the BioNTech COVID-19 vaccine BNT162b2. Up to December 19, 2020, severe …
injection of the BioNTech COVID-19 vaccine BNT162b2. Up to December 19, 2020, severe …
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives
Vaccines are essential public health tools with a favorable safety profile and prophylactic
effectiveness that have historically played significant roles in reducing infectious disease …
effectiveness that have historically played significant roles in reducing infectious disease …
Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations
NG Kounis, I Koniari, C de Gregorio, D Velissaris… - Vaccines, 2021 - mdpi.com
Vaccines constitute the most effective medications in public health as they control and
prevent the spread of infectious diseases and reduce mortality. Similar to other medications …
prevent the spread of infectious diseases and reduce mortality. Similar to other medications …
Allergies and COVID‐19 vaccines: an ENDA/EAACI position paper
Background Anaphylaxis, which is rare, has been reported after COVID‐19 vaccination, but
its management is not standardized. Method Members of the European Network for Drug …
its management is not standardized. Method Members of the European Network for Drug …
Patients with suspected allergic reactions to COVID‐19 vaccines can be safely revaccinated after diagnostic work‐up
TH Rasmussen, CG Mortz, TK Georgsen… - Clinical and …, 2021 - Wiley Online Library
Abstract Background When initiating the Danish vaccination program against COVID‐19, the
incidence of anaphylaxis was estimated to be 10 times higher compared to other virus …
incidence of anaphylaxis was estimated to be 10 times higher compared to other virus …
Adverse reactions to COVID‐19 vaccines: a practical approach
K Rutkowski, R Mirakian, S Till… - Clinical & …, 2021 - Wiley Online Library
COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment
options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the …
options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the …